- Results show significantly longer survival time for patients treated on study
- 97% of patients did not experience disease progression in first 6 months
- Randomized clinical studies assessing this unique immunotherapy are planned
With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM are sharing research results, reporting that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.
SurVaxM was developed at Roswell Park Comprehensive Cancer Center by Robert Fenstermaker, MD, Chair of Neurosurgery, and Michael Ciesielski, PhD, Assistant Professor of Neurosurgery. The vaccine is a new and unique cancer immunotherapy designed to stimulate a multifaceted immune response targeting survivin, a tumor-survival antigen not generally present in nonmalignant cells.
o 
o
